Table 4.

Risk reduction in CHB patients with various treatments and cirrhotic patients with LMV

	HCC			Cirrhosis
	RRR	ARR	NNT	RRR	ARR	NNT
REVEAL Study [8, 9]
LMV/ADV	0.38	0.02	58	0.38	0.03	29
ADV/LMV	0.51	0.02	44	0.51	0.05	22
ETV	0.61	0.03	37	0.61	0.05	18
PEG	0.22	0.01	100	0.22	0.02	50

	RRR	ARR	NNT	Median total cost of LMV
Asian Lamivudine Cirrhotic Study [6]
End point reductiona	0.559322	0.099	10.10101	US$26,100
HCC	0.472973	0.035	28.57143	US$74,567

Note: RRR = relative risk reduction, ARR = absolute risk reduction, NNT = Number needed to treat, LMV = lamivudine, ADV = adefovir, ETV = entecavir, PEG = pegylated interferon

^aDefined as increase in Child-Pugh score of 2 or spontaneous bacterial peritonitis with proven sepsis, renal insufficiency, bleeding gastric or esophageal varices, the development of hepatocellular carcinoma, or death related to liver disease